tradingkey.logo

Intel, Kellanova, Peloton rise premarket; Starbucks slips

Investing.comAug 14, 2024 11:34 AM

Investing.com -- U.S. stock futures traded largely unchanged Wednesday, as investors cautiously await the release of the latest crucial consumer prices data.

Here are some of the biggest premarket U.S. stock movers today

  • Intel (NASDAQ:INTC) stock rose 0.4% after a regulatory filing showed the chipmaker sold its 1.18 million share stake in Arm Holdings (NASDAQ:ARM), up 1.8%, in the second quarter, after saying earlier this month that it would cut more than 15% of its workforce and suspend its dividend amid a pullback in spending.

  • Kellanova (NYSE:K) stock rose 8% after the Wall Street Journal reported that chocolate giant Mars is looking to pay $83.50 for each share in packaged foods maker, a 12% premium to Tuesday’s close, while valuing the firm at over $30 billion.

  • Peloton (NASDAQ:PTON) stock rose 6.3% after the exercise equipment maker announced a partnership with Google's (NASDAQ:GOOGL) Fitbit (NYSE:FIT) to give its premium users access to its fitness content, starting early September.

  • Starbucks (NASDAQ:SBUX) stock fell 0.3%, handing back some of the previous session’s hefty gains after the coffee chain named Chipotle's (NYSE:CMG)'s Brian Niccol as its new CEO, replacing Laxman Narasimhan, who was at the helm for close to a year and a half.

  • UBS (NYSE:UBS) stock rose 3.2% after the Swiss banking giant reported an impressive second-quarter performance, detailing a net profit of $1.14 billion, comfortably surpassing forecasts.

  • Cardinal Health (NYSE:CAH) stock rose 6.7% after the health care services company raised its 2025 fiscal year guidance after strong 2024 results.

  • Tencent Holdings (HK:0700) (OTC:TCEHY) stock will be in focus after the world's largest video game company and operator of the WeChat messaging platform reported an 8% rise in second-quarter revenue, driven by a recovery in its gaming business.

  • Medtronic (NYSE:MDT) stock fell 0.6% after Stifel downgraded its stance on the medical device company to ‘hold’ from buy’, citing a difficult growth outlook.

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

Tradingkey
KeyAI